Otsuka Looks To New Products As Abilify Plunge Bites

Otsuka has added some flesh to the bones of its strategy to fill the hole left by plunging sales of mainstay product Abilify due to generic competition, with new formulations of the atypical antipsychotic and pipeline CNS drugs seen as driving growth over the next few years.